Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of FULIRI Regimen Chemotherapy Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases.

NCT07515963 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT07515963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07515963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of FULIRI Regimen Chemotherapy Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases.
Lead sponsor
Zhongnan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
February 1, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer